Dr. Clay Siegall was interviewed for the online publication Inspirey, a website created to spread the success stories of entrepreneurs around the world. In the interview titled “Dr. Clay Siegall—CEO, Seattle Genetics”, Mike Munter sought to discover the inspiration behind Seattle Genetics, a biotech company.
In the interview, Munter discovered that Dr. Clay Siegall is a firm believer in hard work. Siegall believes that inspired work habits are the key to success and intelligence and network are secondary.
Siegall reveals that the company only became profitable about ten years after the initial public offering. But after hiring a talented sales team and developing a marketing strategy that involves long negotiation as relationship building, they are able to create contracts of 7 or 8 figures. He believes their selling process is rather unique since the marketing strategy is based in building relationships with the clients and negotiating with a great legal team. Because they have unique products, the sales staff is able to represent the company. He believes the sales team may be one of the most important parts in making the company successful. They developed the process after having some financial difficulties in 1999 and 2000. However, Siegall believes they were able to grow from it and become profitable due to their talented sales team.
The company also produces incredibly unique products. They were the first to have an FDA approved ADC. Their drug, ADCETRIS, is an antibody drug conjugate which combines monoclonal antibodies and cell-killing agents to treat cancer. He was inspired to create the company after realizing the lack of choices in cancer treatment, all of which can be very invasive and harmful to the patient. He realized that choosing between the harsh, systemic chemotherapy that can have deadly side effects, or brutal surgeries and amputations did not leave patients with the best options. He created Seattle Genetics to help those patients.
Prior to starting Seattle Genetics, Dr. Siegall worked with the Bristol-Myers Squibb Pharamaceutical Research Institute as a senior researcher. He also worked with the National Caner Institute and the National Institutes of Health. He is not only the CEO and President of Seattle Genetics, but he has also been a key factor in the capital-raising activities for the company. Under his leadership, the company was able to gain $675 million in financing. He is also a thorough researcher with nearly 70 published works and 15 patents. He led Seattle Genetics to create a variety of antibody-based cancer treatments including ADCETRIS, an FDA approved drug available in 65 countries.
Over the last 50 years, one of the great mysteries of cancer treatment is why some patient groups respond incredibly well to treatment, such as chemotherapy, while others barely respond at all. Part of the mystery has to do with the genetic makeup of the tumors themselves, with some tumors being highly susceptible to chemotherapeutic agents, while others are barely affected.
However, with the proliferation of electronic medical records and such technologies as the ability to sequence the human genome being developed over the last few decades, there is great promise for the ability of modern data analysis techniques to yield huge results that have never before been possible.
One of America’s foremost entrepreneurs, Eric Lefkofsky, has co-founded a company, Tempus, which is dedicated to the creation of artificial intelligence applications that can be used by doctors in real-time to greatly enhance their knowledge about given treatment regimes and the likelihood of their patients to respond to them. The Tempus system will use a combination of all available medical records, including the patient’s own genome, in order to provide doctors with the most cutting-edge analyses possible, leading to far more accurate medical decisions taken with regards to the types of treatment patients are given.
Lefkofsky believes that one of the most promising areas of development that will begin to seriously transform the practice of medicine has been the exponential decline in the cost of human genomic sequencing. Lefkofsky points out that in the year 2003, the first time a human genome was sequenced, the cost to do so was over $100 million. Lefkofsky points out that, within the next 10 years, the cost is likely to drop below $100.
Lefkofsky firmly believes that this will open up an entire treasure trove of previously completely untapped data, much of which will prove to be invaluable in the treatment of various types of diseases, particularly cancers. Tempus is now developing applications that will use the human genome itself to give doctors a better picture of their patients’ likely outcomes than has ever been before been possible. Through efforts like these, Lefkofsky is helping to change the face of medicine.
Eric Lefkofsky has been in the business industry for many years. He has worked hard to make sure that things are better for the businesses that he works with and this has given him the chance to do things that are better for the businesses.
The expertise that Eric Lefkofsky has gives him the chance to make sure that things are better for each of the businesses that he is in. He wants to make sure that each business has the chance to make sure that things are working for the business. It has given him the chance to do things that are better and has also allowed him the chance to do different things. When it comes to business, Eric Lefkofsky is confident that the skills he has are the best and are able to make things better for each of the companies that he works with in the following: https://www.bizjournals.com/chicago/news/2017/04/12/groupon-co-founder-moves-to-help-youth-access-art.html click here.
With only a short education career under his belt, Eric Lefkofsky began working in business. He sold carpet when he first started out and this gave him the chance to see what sales was really all about. It also allowed him to see how successful healthcare work he could truly be in sales if only he worked hard for it. He did just that and he continued to work in sales throughout the time that he has been a part of. It was something that he felt would help him later on and he learned that he was really good at doing things in sales.
Now that Eric Lefkofsky has been so successful, he is now able to help other people be successful. He teaches business courses in both sales and doing business with different things. It has been a great deal for people who want to be able to do different things. Eric Lefkofsky has given people the chance to learn what they can do with their businesses and with the businesses that they run. He wants to make sure that each of the people who he works with knows how to do things that are right with the businesses they are in.
Eric Lefkofsky is the current CEO of the major savings site Groupon. He has worked for the company for many years and he continues to offer them the best savings possible. This has allowed him the chance to be successful and has also brought a lot of success to the company. Groupon was a great company before he was the CEO, but it has vastly improved in the time that he has been running the business. He understands how savings is able to help customers of Groupon and how it can help the business that he is in.
With all of the success that Eric Lefkofsky has seen, it is not a bad idea to think that he is going to slow down. This is not the case. Eric Lefkofsky plans to continue being as successful as possible during his time in business. He wants to make sure that everyone gets a chance to get the great deals that he has to offer them. He wants to make sure that everyone can be as successful as him. Unlike other CEOs, he wants the average person to have the chance to be as successful as what he has been in his career.
Clay Siegall is among the founding fathers of Seattle Genetics. This company is involved with biotechnological research with the motive of helping patients of cancer. Currently, Siegall works as the SEO of the company. Siegall is a scientist who specializes in cancer treatments. After graduating with a Genetics Ph.D. from George Washington University, Siegall jump started his career working as an investigator of research at the Bristol/Myers Squibb Pharmaceutical Research Institute. While working here, he was promoted to the post of a principle scientist. He later went on to earn the title of “National Cancer Institute” fellow.
Siegall’s Role in Seattle Genetics
As the CEO of Seattle Genetics, Siegall has led the company to be regarded as a leading authority in the study and manufacture of “antibody-drug conjugates”. It is under his tenure that Seattle Genetics received FDA approval for ADCETRIS. Later on, ADCETRIS merged with Takeda Pharmaceutical to form an international product that is acknowledged in over 65 countries across the globe.
Siegall can also take credit for helping Seattle Genetics receive multiple licenses in connection with the ADCETRIS product. Siegall’s influence has resulted in licenses from AbbVie, GlaxoSmithKline, Pfizer, and Genentech. Dr Siegall further helped Seattle Genetics amass over $1.2 billion in capital from private and public sources. In 2001, Siegall played a central role in Seattle Genetics IPO launch.
Siegall’s Role in Cancer Research
Siegall’s prosperous career is attributed to his efforts and achievements with regards to cancer research. Siegall’s hard work, dedication, and commitment have all been directed to identifying a cancer cure. It is his desire to find a solution to this life threatening condition that caused him to champion research on alternative treatments. Siegall has been involved in several medical and scientific committees that are focused on addressing the cancer menace. His full involvement in the fight against cancer caused him to receive an award given every year to the University of Maryland Alumni for math, natural sciences, and computers. He had initially been awarded with the “Pacific Northwest Ernst and Young Entrepreneur of the Year”.
Apart from receiving coveted awards, Siegall owns 15 patents and is set to have more as he continues his journey in the search for a cancer cure. His publications address his discoveries and the progress of his research. These publications have helped the health sector identify more efficient and effective cancer treatments.